Boron-based hybrids as novel scaffolds for the development of drugs with neuroprotective properties.

Cacciatore I, Turkez H, Di Rienzo A, Ciulla M, Mardinoglu A, Di Stefano A

RSC Med Chem 12 (11) 1944-1949 [2021-11-17; online 2021-08-13]

Novel boron-based compounds (BBCs) were synthesized and evaluated as potential candidates for the development of novel drugs against Alzheimer's disease (AD). The neuroprotective profile of novel BBCs was evaluated using Aβ1-42-treated-SH-SY5Y cells while their antioxidant activity was evaluated by total antioxidant capacity (TAC) and total oxidative status (TOS) assays. Results showed that BLA (a novel boron-based hybrid containing an antioxidant portion) inhibited cell death induced by Aβ1-42-exposure in differentiated SH-SY5Y cells, resulting in an increase in cell viability by 25-33% (MTT assay) and by 63-71% (LDH assay) in a concentration range of 25-100 μM. Antioxidant assays demonstrated a good capability of BLA to counteract the oxidative status. Moreover, BLA possessed a significant ability to inhibit acetylcholinesterase (AChE) (22.96% at 50 μM), an enzyme whose enzymatic activity is increased in AD patients. In the present work, absorption and distribution properties of boron-based hybrids were predicted using Pre-ADMET software. In vitro preliminary results suggested that boron-based hybrids could be new structural scaffolds for the development of novel drugs for the management of AD.

Adil Mardinoglu

SciLifeLab Fellow

PubMed 34825189

DOI 10.1039/d1md00177a

Crossref 10.1039/d1md00177a

pmc: PMC8597428
pii: d1md00177a

Publications 9.5.0